Addex Therapeutics Ltd
ADXN8.849USD
+0.749+9.24%
Market hours （ET）Quotes delayed by 15 min
7.25MMarket Cap
0.96P/E TTM
More Details of Addex Therapeutics Ltd Company
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
Company Info
Ticker SymbolADXN
Company nameAddex Therapeutics Ltd
IPO dateMay 22, 2007
CEOMr. Tim Dyer
Number of employees2
Security typeOrdinary Share
Fiscal year-endMay 22
AddressChemin des Mines, 9
CityPLAN-LES-OUATES
Stock exchangeSIX Swiss Exchange
CountrySwitzerland
Postal code1202
Phone41228841555
Websitehttps://www.addextherapeutics.com/en/
Ticker SymbolADXN
IPO dateMay 22, 2007
CEOMr. Tim Dyer
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Mikhail Kalinichev
Dr. Mikhail Kalinichev
Member of the Executive Management, Head of Translational Science
Member of the Executive Management, Head of Translational Science
--
--
Dr. Raymond G. (Ray) Hill
Dr. Raymond G. (Ray) Hill
Non-Executive Independent Member of the Board of Directors
Non-Executive Independent Member of the Board of Directors
--
--
Mr. Lenaic Teyssedou
Mr. Lenaic Teyssedou
Member of the Executive Management, Head of Finance
Member of the Executive Management, Head of Finance
--
--
Dr. Vincent Lawton
Dr. Vincent Lawton
Independent Non-Executive Chairman of the Board of Directors
Independent Non-Executive Chairman of the Board of Directors
--
--
Mr. Jake R. Nunn
Mr. Jake R. Nunn
Non-Executive Independent Member of the Board of Directors
Non-Executive Independent Member of the Board of Directors
--
--
Mr. Tim Dyer
Mr. Tim Dyer
Chief Executive Officer, Co-Founder, Member of the Executive Management, Director
Chief Executive Officer, Co-Founder, Member of the Executive Management, Director
--
--
Dr. Isaac Manke
Dr. Isaac Manke
Non-Executive Independent Member of the Board of Directors
Non-Executive Independent Member of the Board of Directors
--
--
Dr. Roger G. Mills
Dr. Roger G. Mills
Member of the Executive Management, Chief Medical Officer, Member of the Board of Directors
Member of the Executive Management, Chief Medical Officer, Member of the Board of Directors
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Mikhail Kalinichev
Dr. Mikhail Kalinichev
Member of the Executive Management, Head of Translational Science
Member of the Executive Management, Head of Translational Science
--
--
Dr. Raymond G. (Ray) Hill
Dr. Raymond G. (Ray) Hill
Non-Executive Independent Member of the Board of Directors
Non-Executive Independent Member of the Board of Directors
--
--
Mr. Lenaic Teyssedou
Mr. Lenaic Teyssedou
Member of the Executive Management, Head of Finance
Member of the Executive Management, Head of Finance
--
--
Dr. Vincent Lawton
Dr. Vincent Lawton
Independent Non-Executive Chairman of the Board of Directors
Independent Non-Executive Chairman of the Board of Directors
--
--
Mr. Jake R. Nunn
Mr. Jake R. Nunn
Non-Executive Independent Member of the Board of Directors
Non-Executive Independent Member of the Board of Directors
--
--
Mr. Tim Dyer
Mr. Tim Dyer
Chief Executive Officer, Co-Founder, Member of the Executive Management, Director
Chief Executive Officer, Co-Founder, Member of the Executive Management, Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Feb 23
Updated: Sun, Feb 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Citadel Advisors LLC
1.10%
GAMMA Investing LLC
0.01%
Other
98.89%
Shareholders
Shareholders
Proportion
Citadel Advisors LLC
1.10%
GAMMA Investing LLC
0.01%
Other
98.89%
Shareholder Types
Shareholders
Proportion
Hedge Fund
1.10%
Investment Advisor/Hedge Fund
0.01%
Other
98.89%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
12
12.04K
1.13%
-165.56K
2025Q1
16
13.11K
1.23%
-176.53K
2024Q4
17
15.10K
1.41%
-160.92K
2024Q3
22
37.43K
5.74%
-146.56K
2024Q2
21
38.45K
5.90%
-143.53K
2024Q1
20
36.44K
5.64%
-145.16K
2023Q4
19
195.87K
20.93%
+138.26K
2023Q3
18
73.39K
96.72%
+38.94K
2023Q2
18
50.23K
7.45%
-253.79K
2023Q1
17
333.00K
49.67%
+248.23K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Citadel Advisors LLC
11.74K
1.1%
-338.00
-2.80%
Mar 31, 2025
GAMMA Investing LLC
1.19K
0.11%
+182.00
+18.00%
Mar 31, 2025
Morgan Stanley & Co. LLC
100.00
0.01%
-1.80K
-94.74%
Mar 31, 2025
Rhumbline Advisers Ltd. Partnership
72.00
0.01%
-35.00
-32.71%
Mar 31, 2025
SBI Securities Co., Ltd.
5.00
0%
--
--
Mar 31, 2025
J. Stern & Co. LLP
--
0%
-107.83K
-100.00%
Mar 31, 2024
Armistice Capital LLC
--
0%
-43.00K
-100.00%
Mar 31, 2024
Baader Bank AG
--
0%
-960.00
-100.00%
Dec 31, 2023
Jane Street Capital, L.L.C.
--
0%
-529.00
-100.00%
Dec 31, 2023
New Enterprise Associates (NEA)
--
0%
-9.00K
-100.00%
Mar 31, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 06, 2023
Merger
20<1
Oct 06, 2023
Merger
20<1
Oct 06, 2023
Merger
20<1
Oct 06, 2023
Merger
20<1
Date
Type
Ratio
Oct 06, 2023
Merger
20<1
Oct 06, 2023
Merger
20<1
Oct 06, 2023
Merger
20<1
Oct 06, 2023
Merger
20<1
